{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T13:46:17Z","timestamp":1792417577624,"version":"4.4.0"},"reference-count":33,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,5,1]],"date-time":"2021-05-01T00:00:00Z","timestamp":1619827200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,5,1]],"date-time":"2021-05-01T00:00:00Z","timestamp":1619827200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,5,1]],"date-time":"2021-05-01T00:00:00Z","timestamp":1619827200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2021,5,1]],"date-time":"2021-05-01T00:00:00Z","timestamp":1619827200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2021,5,1]],"date-time":"2021-05-01T00:00:00Z","timestamp":1619827200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2021,5,1]],"date-time":"2021-05-01T00:00:00Z","timestamp":1619827200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2021,5,1]],"date-time":"2021-05-01T00:00:00Z","timestamp":1619827200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100014477","name":"National Health Insurance Administration","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100014477","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004737","name":"National Health Research Institutes","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004737","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jns-journal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of the Neurological Sciences"],"published-print":{"date-parts":[[2021,5]]},"DOI":"10.1016\/j.jns.2021.117412","type":"journal-article","created":{"date-parts":[[2021,3,24]],"date-time":"2021-03-24T01:24:14Z","timestamp":1616549054000},"page":"117412","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":25,"special_numbering":"C","title":["Calcium Channel blockers are associated with reduced risk of Parkinson's disease in patients with hypertension: A population-based retrospective cohort study"],"prefix":"10.1016","volume":"424","author":[{"given":"Yuan-Fu","family":"Tseng","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hsiu-Chen","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jane Chen-Jui","family":"Chao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chien-Yeh","family":"Hsu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hsiu-Li","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jns.2021.117412_bb0005","doi-asserted-by":"crossref","first-page":"1257","DOI":"10.1016\/S1474-4422(16)30230-7","article-title":"The epidemiology of Parkinson\u2019s disease: risk factors and prevention","volume":"15","author":"Ascherio","year":"2016","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.jns.2021.117412_bb0010","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1159\/000113678","article-title":"Basic research on dopamine in Parkinson\u2019s disease and the discovery of the nigrostriatal dopamine pathway: the view of an eyewitness","volume":"5","author":"Hornykiewicz","year":"2008","journal-title":"Neurodegener. Dis."},{"key":"10.1016\/j.jns.2021.117412_bb0015","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1038\/nrn.2016.178","article-title":"Selective neuronal vulnerability in Parkinson disease","volume":"18","author":"Surmeier","year":"2017","journal-title":"Nat. Rev. Neurosci."},{"key":"10.1016\/j.jns.2021.117412_bb0020","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1016\/j.neuroscience.2011.08.045","article-title":"The role of calcium and mitochondrial oxidant stress in the loss of substantia nigra pars compacta dopaminergic neurons in Parkinson's disease","volume":"198","author":"Surmeier","year":"2011","journal-title":"Neuroscience"},{"key":"10.1016\/j.jns.2021.117412_bb0025","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1111\/j.1476-5381.1994.tb17068.x","article-title":"Effects of dihydropyridine calcium antagonists on rat midbrain dopaminergic neurones","volume":"113","author":"Mercuri","year":"1994","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.jns.2021.117412_bb0030","doi-asserted-by":"crossref","first-page":"10736","DOI":"10.1074\/jbc.R112.410530","article-title":"Calcium, bioenergetics, and neuronal vulnerability in Parkinson\u2019s disease","volume":"288","author":"Surmeier","year":"2013","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.jns.2021.117412_bb0035","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.1038\/nature05865","article-title":"Rejuvenation' protects neurons in mouse models of Parkinson's disease","volume":"447","author":"Chan","year":"2007","journal-title":"Nature"},{"key":"10.1016\/j.jns.2021.117412_bb0040","doi-asserted-by":"crossref","first-page":"696","DOI":"10.1038\/nature09536","article-title":"Oxidant stress evoked by pacemaking in dopaminergic neurons is attenuated by DJ-1","volume":"468","author":"Guzman","year":"2010","journal-title":"Nature"},{"key":"10.1016\/j.jns.2021.117412_bb0045","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1196\/annals.1427.002","article-title":"Oxidative stress and energy crises in neuronal dysfunction","volume":"1147","author":"Nicholls","year":"2008","journal-title":"Ann. N. Y. Acad. Sci."},{"key":"10.1016\/j.jns.2021.117412_bb0050","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1111\/j.1474-9726.2007.00275.x","article-title":"Calcium and neurodegeneration","volume":"6","author":"Mattson","year":"2007","journal-title":"Aging Cell"},{"key":"10.1016\/j.jns.2021.117412_bb0055","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1146\/annurev-pharmtox-010818-021214","article-title":"The potential of L-type calcium channels as a drug target for Neuroprotective therapy in Parkinson\u2019s disease","volume":"59","author":"Liss","year":"2019","journal-title":"Annu. Rev. Pharmacol. Toxicol."},{"key":"10.1016\/j.jns.2021.117412_bb0060","doi-asserted-by":"crossref","first-page":"1414","DOI":"10.1038\/nn.3209","article-title":"Calcium entry induces mitochondrial oxidant stress in vagal neurons at risk in Parkinson\u2019s disease","volume":"15","author":"Goldberg","year":"2012","journal-title":"Nat. Neurosci."},{"key":"10.1016\/j.jns.2021.117412_bb0065","doi-asserted-by":"crossref","first-page":"5944","DOI":"10.1523\/JNEUROSCI.21-16-05944.2001","article-title":"Neuronal Ca(V)1.3alpha(1) L-type channels activate at relatively hyperpolarized membrane potentials and are incompletely inhibited by dihydropyridines","volume":"21","author":"Xu","year":"2001","journal-title":"J. Neurosci."},{"key":"10.1016\/j.jns.2021.117412_bb0070","doi-asserted-by":"crossref","first-page":"1438","DOI":"10.1212\/01.wnl.0000303818.38960.44","article-title":"Use of antihypertensives and the risk of Parkinson disease","volume":"70","author":"Becker","year":"2008","journal-title":"Neurology"},{"key":"10.1016\/j.jns.2021.117412_bb0075","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1002\/ana.21937","article-title":"L-type calcium channel blockers and Parkinson disease in Denmark","volume":"67","author":"Ritz","year":"2010","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.jns.2021.117412_bb0080","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1093\/aje\/kwr362","article-title":"Use of calcium channel blockers and Parkinson\u2019s disease","volume":"175","author":"Pasternak","year":"2012","journal-title":"Am. J. Epidemiol."},{"key":"10.1016\/j.jns.2021.117412_bb0085","article-title":"Antihypertensive agents and risk of Parkinson's disease: a nationwide cohort study","volume":"9","author":"Lee","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/j.jns.2021.117412_bb0090","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/j.parkreldis.2006.08.011","article-title":"Calcium channel blockers and beta-blockers in relation to Parkinson\u2019s disease","volume":"13","author":"Ton","year":"2007","journal-title":"Parkinsonism Relat. Disord."},{"key":"10.1016\/j.jns.2021.117412_bb0095","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1159\/000235641","article-title":"Antihypertensive agents and risk of Parkinson's disease, essential tremor and dementia: a population-based prospective study (NEDICES)","volume":"33","author":"Louis","year":"2009","journal-title":"Neuroepidemiology"},{"key":"10.1016\/j.jns.2021.117412_bb0100","doi-asserted-by":"crossref","first-page":"1818","DOI":"10.1002\/mds.23191","article-title":"Calcium channel blocker use and risk of Parkinson\u2019s disease","volume":"25","author":"Simon","year":"2010","journal-title":"Mov. Disord."},{"key":"10.1016\/j.jns.2021.117412_bb0105","doi-asserted-by":"crossref","first-page":"1094","DOI":"10.1161\/HYPERTENSIONAHA.111.171249","article-title":"Association of blood pressure and hypertension with the risk of Parkinson disease: the national FINRISK study","volume":"57","author":"Qiu","year":"2011","journal-title":"Hypertension"},{"key":"10.1016\/j.jns.2021.117412_bb0110","doi-asserted-by":"crossref","first-page":"162","DOI":"10.3389\/fneur.2018.00162","article-title":"Hypertension and diagnosis of Parkinson\u2019s disease: a meta-analysis of cohort studies","volume":"9","author":"Hou","year":"2018","journal-title":"Front. Neurol."},{"key":"10.1016\/j.jns.2021.117412_bb0115","doi-asserted-by":"crossref","first-page":"1419","DOI":"10.1007\/s10072-020-04277-w","article-title":"Association of orthostatic hypotension with Parkinson\u2019s disease: a meta-analysis","volume":"41","author":"Mu","year":"2020","journal-title":"Neurol. Sci."},{"key":"10.1016\/j.jns.2021.117412_bb0120","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1002\/pds.819","article-title":"How well do patients report noncompliance with antihypertensive medications?: a comparison of self-report versus filled prescriptions","volume":"13","author":"Wang","year":"2004","journal-title":"Pharmacoepidemiol. Drug Saf."},{"key":"10.1016\/j.jns.2021.117412_bb0125","doi-asserted-by":"crossref","first-page":"2226","DOI":"10.1002\/mds.23828","article-title":"Drug-induced parkinsonism: a review of 17 years\u2019 experience in a regional pharmacovigilance center in France","volume":"26","author":"Bondon-Guitton","year":"2011","journal-title":"Mov. Disord."},{"key":"10.1016\/j.jns.2021.117412_bb0130","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1016\/bs.irn.2019.10.010","article-title":"Secondary parkinsonism due to drugs, vascular lesions, tumors, trauma, and other insults","volume":"149","author":"H\u00f6llerhage","year":"2019","journal-title":"Int. Rev. Neurobiol."},{"key":"10.1016\/j.jns.2021.117412_bb0135","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1016\/S1353-8020(98)00032-7","article-title":"Calcium channel blocker-induced parkinsonism: clinical features and comparisons with Parkinson\u2019s disease","volume":"4","author":"Garc\u00eda-Ruiz","year":"1998","journal-title":"Parkinsonism Relat. Disord."},{"key":"10.1016\/j.jns.2021.117412_bb0140","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1002\/mds.870100120","article-title":"Parkinsonism induced by amlodipine","volume":"10","author":"Sempere","year":"1995","journal-title":"Mov. Disord."},{"key":"10.1016\/j.jns.2021.117412_bb0145","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1136\/pgmj.2008.073312","article-title":"Drug induced parkinsonism: a common cause of parkinsonism in older people","volume":"85","author":"Thanvi","year":"2009","journal-title":"Postgrad. Med. J."},{"key":"10.1016\/j.jns.2021.117412_bb0150","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.1126\/science.aam9080","article-title":"Dopamine oxidation mediates mitochondrial and lysosomal dysfunction in Parkinson's disease","volume":"357","author":"Burbulla","year":"2017","journal-title":"Science"},{"key":"10.1016\/j.jns.2021.117412_bb0155","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1016\/j.neuint.2016.07.003","article-title":"Nimodipine, an L-type calcium channel blocker attenuates mitochondrial dysfunctions to protect against 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced parkinsonism in mice","volume":"99","author":"Singh","year":"2016","journal-title":"Neurochem. Int."},{"key":"10.1016\/j.jns.2021.117412_bb0160","doi-asserted-by":"crossref","first-page":"3","DOI":"10.3233\/JPD-190002","article-title":"Clinical trial highlights: phase III study in spotlight","volume":"9","author":"McFarthing","year":"2019","journal-title":"J. Parkinsons Dis."},{"key":"10.1016\/j.jns.2021.117412_bb0165","doi-asserted-by":"crossref","first-page":"2283","DOI":"10.1093\/brain\/114.5.2283","article-title":"Ageing and Parkinson's disease: substantia nigra regional selectivity","volume":"114","author":"Fearnley","year":"1991","journal-title":"Brain"}],"container-title":["Journal of the Neurological Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022510X21001052?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022510X21001052?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,20]],"date-time":"2025-09-20T15:54:45Z","timestamp":1758383685000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0022510X21001052"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,5]]},"references-count":33,"alternative-id":["S0022510X21001052"],"URL":"https:\/\/doi.org\/10.1016\/j.jns.2021.117412","relation":{},"ISSN":["0022-510X"],"issn-type":[{"value":"0022-510X","type":"print"}],"subject":[],"published":{"date-parts":[[2021,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Calcium Channel blockers are associated with reduced risk of Parkinson's disease in patients with hypertension: A population-based retrospective cohort study","name":"articletitle","label":"Article Title"},{"value":"Journal of the Neurological Sciences","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jns.2021.117412","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"117412"}}